X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (53) 53
humans (49) 49
index medicus (35) 35
female (29) 29
male (26) 26
united states (26) 26
middle aged (25) 25
united states food and drug administration (25) 25
aged (22) 22
drug approval (21) 21
cancer (19) 19
adult (18) 18
chemotherapy (18) 18
clinical trials (12) 12
fda (12) 12
treatment outcome (11) 11
aged, 80 and over (9) 9
antineoplastic agents (9) 9
antineoplastic agents - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
care and treatment (9) 9
drug therapy (9) 9
pharmacology & pharmacy (9) 9
regulatory issues (9) 9
abridged index medicus (8) 8
docetaxel (8) 8
medicine & public health (8) 8
randomized controlled trials as topic (8) 8
regulatory issues: fda (8) 8
antimitotic agents (7) 7
disease-free survival (7) 7
immunotherapy (7) 7
neoplasms - drug therapy (7) 7
pembrolizumab (7) 7
research (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
clinical trials as topic (6) 6
colorectal cancer (6) 6
nivolumab (6) 6
pharmacology/toxicology (6) 6
trial (6) 6
disease progression (5) 5
lung neoplasms - drug therapy (5) 5
multiple myeloma (5) 5
multiple myeloma - drug therapy (5) 5
neoplasm metastasis (5) 5
pharmaceutical industry (5) 5
tumors (5) 5
5-fluorouracil (4) 4
analysis (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antimetabolites, antineoplastic - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
bortezomib (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
clinical trials as topic - methods (4) 4
clinical-trials (4) 4
colorectal neoplasms - drug therapy (4) 4
drug administration schedule (4) 4
drug development (4) 4
fda approval (4) 4
fluorouracil (4) 4
fluorouracil - administration & dosage (4) 4
internal medicine (4) 4
irinotecan (4) 4
leucovorin (4) 4
maximum tolerated dose (4) 4
medical research (4) 4
medicine, general & internal (4) 4
neutropenia - chemically induced (4) 4
non-small cell lung cancer (4) 4
non‐small cell lung cancer (4) 4
product development (4) 4
survival (4) 4
antibodies, monoclonal - adverse effects (3) 3
antineoplastic agents - pharmacology (3) 3
b7-h1 antigen - analysis (3) 3
blood transfusion (3) 3
breast cancer (3) 3
breast neoplasms - drug therapy (3) 3
camptothecin - administration & dosage (3) 3
camptothecin - analogs & derivatives (3) 3
cisplatin (3) 3
clinical trial (3) 3
colorectal carcinoma (3) 3
cyclophosphamide (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
development and progression (3) 3
dosage and administration (3) 3
drugs (3) 3
erlotinib (3) 3
infusions, intravenous (3) 3
leukemia (3) 3
lung cancer (3) 3
lung neoplasms - pathology (3) 3
lymphomas (3) 3
management (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Academic Radiology, ISSN 1076-6332, 2007, Volume 14, Issue 3, pp. 330 - 339
Journal Article
The Oncologist, ISSN 1083-7159, 03/2018, Volume 23, Issue 3, pp. 328 - 336
Background Evidence from cancer clinical trials can be difficult to generalize to real‐world patient populations, but can be complemented by real‐world... 
Pembrolizumab | Demography | Non‐small cell lung cancer | Electronic health records | Nivolumab | ONCOLOGY | Non-small cell lung cancer | DOCETAXEL | CHEMOTHERAPY | Lung Cancer
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2438 - 2441
Journal Article
Journal of Investigative Medicine, ISSN 1708-8267, 2004, Volume 52, Issue 4, pp. 217 - 219
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 33, pp. 3745 - 3752
Clinical trial eligibility criteria are necessary to define the patient population under study and improve trial safety. However, there are concerns that... 
ENROLLMENT | MANAGEMENT | ONCOLOGY | CANCER | METASTASES | Drug Discovery - methods | Neoplasms - therapy | Clinical Trials as Topic - methods | Early Detection of Cancer - methods | History, 21st Century | Humans | Special Series ASCO Special
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 19, pp. 1791 - 1795
The FDA required labeling changes for the programmed cell death 1 inhibitor pembrolizumab and thalidomide-analogue immunomodulatory agents to include... 
MEDICINE, GENERAL & INTERNAL | Usage | Immunotherapy | Patient outcomes | Analysis | Multiple myeloma | Outcome and process assessment (Health Care) | Drug therapy | PD-1 protein | Immunomodulation | Mortality | Clinical trials | Cytotoxicity | Oncology | Patients | Survival analysis | Pembrolizumab | Cell death | Response rates | Lymphomas | Thalidomide | Drug dosages | Apoptosis
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 229 - 239
Journal Article